Vantage logo

Deals and data in the offing for Oncimmune

Oncimmune is not the only company looking to use the immune system to diagnose cancer. But its growth plans are intense, and it intends to prove the economic benefits of…

Vantage logo

Oncocyte banks on a new kind of liquid biopsy

The Biotime-backed group believes it can use immune system gene expression levels to detect lung cancer earlier. But another trial will be necessary before the test can…

Vantage logo

Check-Cap auditions for its screen debut

Check-Cap has a new spin on capsule endoscopy, using X-rays instead of a visual camera. But more compelling clinical data will be necessary if it is to position its…

Vantage logo

Illumina bets on Pacific, not nanopores

Illumina’s $1.2bn buy of Pacific Biosciences raises questions about why it shunned another long-read sequencing player, Oxford Nanopore Technologies.